{
    "clinical_study": {
        "@rank": "70445", 
        "arm_group": [
            {
                "arm_group_label": "LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)"
            }, 
            {
                "arm_group_label": "LY3002813-Single then multiple 0.3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV"
            }, 
            {
                "arm_group_label": "LY3002813-Single then multiple 1 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV"
            }, 
            {
                "arm_group_label": "LY3002813-Single then multiple 3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV"
            }, 
            {
                "arm_group_label": "LY3002813-Single then multiple 10 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV"
            }, 
            {
                "arm_group_label": "Placebo-Single then multiple", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given once, then every 4 weeks for up to 16 weeks IV"
            }, 
            {
                "arm_group_label": "LY3002813-SC", 
                "arm_group_type": "Experimental", 
                "description": "Up to 3 mg/kg LY3002813 given once subcutaneously (SC)"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the safety of LY3002813 by looking at adverse events. The study will\n      also look at the effect the body has on LY3002813. Study participants will have mild\n      cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.\n\n      There will be six groups of study participants.  Five groups will receive a single dose of\n      LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo\n      given as an injection into a vein. Approximately 12 weeks will pass between the single dose\n      and the first multiple dose. One group of participants will receive a single dose of\n      LY3002813 given as an injection under the skin."
        }, 
        "brief_title": "A Study of LY3002813 in Participants With Alzheimer's Disease", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Present with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or\n             mild-to-moderate AD\n\n          -  Men or nonfertile women, at least 50 years of age. Nonfertile is defined as\n             hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year\n\n          -  Have a caregiver/study informant who provides a separate written informed consent to\n             participate\n\n          -  Have adequate vision and hearing for neuropsychological testing in the opinion of the\n             investigator\n\n          -  Positive florbetapir scan\n\n        Exclusion Criteria:\n\n          -  History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous\n             malformation, or carotid artery occlusion, or stroke or epilepsy\n\n          -  Do not have a reliable caregiver/study informant who is in frequent contact with the\n             participant, who will accompany the participant to the office and/or be available by\n             telephone at designated times, and will monitor administration of prescribed\n             medications\n\n          -  Have any contraindications for magnetic resonance imaging (MRI) studies, including\n             claustrophobia, the presence of contraindicated metal (ferromagnetic) implants,\n             cardiac pacemaker\n\n          -  Are being monitored for radiation due to occupational exposure to ionized radiation,\n             or exposure to ionizing radiation within last 12 months from an investigational study\n\n          -  Have allergies to humanized monoclonal antibodies, including proteins and\n             diphenhydramine, epinephrine, and methylprednisolone\n\n          -  Have gamma globulin therapy within the last year\n\n          -  Previously dosed in any other study investigating active immunization against amyloid\n             beta (A\u03b2)\n\n          -  Previously dosed in any other study investigating passive immunization against A\u03b2\n             within the last 6 months\n\n          -  History within the past 5 years of a primary or recurrent malignant disease with the\n             exception of resected cutaneous squamous cell carcinoma in situ, basal cell\n             carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal\n             prostate-specific antigen post resection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837641", 
            "org_study_id": "15082", 
            "secondary_id": "I5T-MC-AACC"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg", 
                    "LY3002813-Single then multiple 0.3 mg/kg", 
                    "LY3002813-Single then multiple 1 mg/kg", 
                    "LY3002813-Single then multiple 3 mg/kg", 
                    "LY3002813-Single then multiple 10 mg/kg"
                ], 
                "description": "Administered IV", 
                "intervention_name": "LY3002813-IV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "LY3002813-SC", 
                "description": "Administered SC", 
                "intervention_name": "LY3002183-SC", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo-Single then multiple", 
                "description": "Administered IV", 
                "intervention_name": "Placebo-IV", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 16, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84106"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Sumida-Ku", 
                        "country": "Japan", 
                        "zip": "130-0004"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "111-0052"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Japan"
            ]
        }, 
        "number_of_arms": "7", 
        "official_title": "A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 up to Day 253"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837641"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813", 
                "safety_issue": "No", 
                "time_frame": "Predose up to Day 253"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3002813", 
                "safety_issue": "No", 
                "time_frame": "Predose up to Day 253"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}